Olga Nemirovskiy

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis
    M P Hellio Le Graverand
    Pfizer Global Research and Development, Ann Arbor, MI, USA Pfizer Global Research and Development, St Louis, MO, USA
    Osteoarthritis Cartilage 14:1189-95. 2006
  2. doi request reprint Pharmacokinetic/pharmacodynamic (PK/PD) differentiation of native and PEGylated recombinant human growth hormone (rhGH and PEG-rhGH) in the rat model of osteoarthritis
    Olga Nemirovskiy
    Pfizer Global Research and Development, St Louis Laboratories, St Louis, MO 63017, USA
    Xenobiotica 40:586-92. 2010
  3. doi request reprint Plasma 3-nitrotyrosine is a biomarker in animal models of arthritis: Pharmacological dissection of iNOS' role in disease
    Olga V Nemirovskiy
    Pfizer Global Research and Development, St Louis Laboratories, 700 Chesterfield Parkway, St Louis, MO 63017, USA
    Nitric Oxide 20:150-6. 2009
  4. doi request reprint Discovery and development of the N-terminal procollagen type II (NPII) biomarker: a tool for measuring collagen type II synthesis
    O V Nemirovskiy
    Pfizer Global Research and Development, St Louis, MO 63017, USA
    Osteoarthritis Cartilage 16:1494-500. 2008
  5. ncbi request reprint Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo
    O V Nemirovskiy
    Pfizer Global Research and Development, St Louis, MO 63017, USA
    Anal Biochem 361:93-101. 2007
  6. ncbi request reprint Clinical validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide: A biomarker of matrix metalloproteinase activity and osteoarthritis in human urine
    Wenlin Wendy Li
    Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI 48105, USA
    Anal Biochem 369:41-53. 2007
  7. doi request reprint Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: confirmation by multivariate analysis that modulation of type II collagen and aggrecan degradation pepti
    Steven Settle
    Pfizer Global Research and Development, St Louis, Missouri, USA
    Arthritis Rheum 62:3006-15. 2010
  8. doi request reprint Design and validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide in human urine: application as a biomarker of osteoarthritis
    Olga Nemirovskiy
    Pfizer Global Research and Development, St Louis Laboratories, St Louis, MO, USA
    Methods Mol Biol 641:253-70. 2010
  9. ncbi request reprint Identification of an ADAMTS-4 cleavage motif using phage display leads to the development of fluorogenic peptide substrates and reveals matrilin-3 as a novel substrate
    Robert Hills
    Pfizer Global Research and Development, St Louis, Missouri 63017, USA
    J Biol Chem 282:11101-9. 2007
  10. doi request reprint Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1
    Mark E Schnute
    Pfizer Global Research and Development, St Louis Laboratories, Chesterfield, MO 63017, USA
    Biochem J 444:79-88. 2012

Detail Information

Publications12

  1. ncbi request reprint Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis
    M P Hellio Le Graverand
    Pfizer Global Research and Development, Ann Arbor, MI, USA Pfizer Global Research and Development, St Louis, MO, USA
    Osteoarthritis Cartilage 14:1189-95. 2006
    ..To examine whether urine concentrations of type II collagen neoepitope (uTIINE) distinguish subjects with progressive radiographic and/or symptomatic knee osteoarthritis (OA) from those with stable disease...
  2. doi request reprint Pharmacokinetic/pharmacodynamic (PK/PD) differentiation of native and PEGylated recombinant human growth hormone (rhGH and PEG-rhGH) in the rat model of osteoarthritis
    Olga Nemirovskiy
    Pfizer Global Research and Development, St Louis Laboratories, St Louis, MO 63017, USA
    Xenobiotica 40:586-92. 2010
    ..In order to develop PEG-rhGH as an IA therapeutic treatment for OA, careful dose selection is necessary to avoid systemic effects while retaining its anabolic efficacy in the joint...
  3. doi request reprint Plasma 3-nitrotyrosine is a biomarker in animal models of arthritis: Pharmacological dissection of iNOS' role in disease
    Olga V Nemirovskiy
    Pfizer Global Research and Development, St Louis Laboratories, 700 Chesterfield Parkway, St Louis, MO 63017, USA
    Nitric Oxide 20:150-6. 2009
    ..3-NT determination allowed for better elucidation of the role of iNOS in RA and OA disease pathology and provided proof of pharmacology for NOS inhibitors in animal models of RA and OA...
  4. doi request reprint Discovery and development of the N-terminal procollagen type II (NPII) biomarker: a tool for measuring collagen type II synthesis
    O V Nemirovskiy
    Pfizer Global Research and Development, St Louis, MO 63017, USA
    Osteoarthritis Cartilage 16:1494-500. 2008
    ..The ability to quantify the procollagen peptides in biological fluids would enable a better understanding of OA disease pathology and provide means for assessing the proof of mechanism of anabolic disease modifying OA drugs (DMOADs)...
  5. ncbi request reprint Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo
    O V Nemirovskiy
    Pfizer Global Research and Development, St Louis, MO 63017, USA
    Anal Biochem 361:93-101. 2007
    ..The utility of this peptide to monitor collagenase activity in vivo has been demonstrated through its detailed characterization in HAC explants as well as in the urine of human and other preclinical species...
  6. ncbi request reprint Clinical validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide: A biomarker of matrix metalloproteinase activity and osteoarthritis in human urine
    Wenlin Wendy Li
    Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI 48105, USA
    Anal Biochem 369:41-53. 2007
    ..The method was applied to analyze human urine samples from clinical studies investigating the utility of uTIINE as a potential biomarker for OA...
  7. doi request reprint Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: confirmation by multivariate analysis that modulation of type II collagen and aggrecan degradation pepti
    Steven Settle
    Pfizer Global Research and Development, St Louis, Missouri, USA
    Arthritis Rheum 62:3006-15. 2010
    ..To demonstrate that the novel highly selective matrix metalloproteinase 13 (MMP-13) inhibitor PF152 reduces joint lesions in adult dogs with osteoarthritis (OA) and decreases biomarkers of cartilage degradation...
  8. doi request reprint Design and validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide in human urine: application as a biomarker of osteoarthritis
    Olga Nemirovskiy
    Pfizer Global Research and Development, St Louis Laboratories, St Louis, MO, USA
    Methods Mol Biol 641:253-70. 2010
    ..The generalized approach can be used as a follow-up to studies whereby proteomics-based urinary biomarkers are identified and an assay needs to be developed. Considerations for the validation of such an assay are described...
  9. ncbi request reprint Identification of an ADAMTS-4 cleavage motif using phage display leads to the development of fluorogenic peptide substrates and reveals matrilin-3 as a novel substrate
    Robert Hills
    Pfizer Global Research and Development, St Louis, Missouri 63017, USA
    J Biol Chem 282:11101-9. 2007
    ..When tested, recombinant ADAMTS-4 effectively cleaved intact matrilin-3 at the predicted motif at Glu435/Ala436 generating two species of 45 and 5 kDa...
  10. doi request reprint Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1
    Mark E Schnute
    Pfizer Global Research and Development, St Louis Laboratories, Chesterfield, MO 63017, USA
    Biochem J 444:79-88. 2012
    ..PF-543 is the most potent inhibitor of SphK1 described to date and it will be useful for dissecting specific roles of SphK1-driven S1P signalling...
  11. doi request reprint A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation
    James Gierse
    Pfizer Inflammation Research, Chesterfield, MO 63017, USA
    J Pharmacol Exp Ther 334:310-7. 2010
    ..Furthermore, a close pharmacokinetic/pharmacodynamic relationship was observed, which suggests that LPA is rapidly formed and degraded in vivo. PF-8380 can serve as a tool compound for elucidating LPA's role in inflammation...
  12. doi request reprint Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis
    Mark E Schnute
    Global Research and Development, Pfizer Inc, 700 Chesterfield Parkway West, St Louis, MO 63017, USA
    Bioorg Med Chem Lett 20:576-80. 2010
    ..Compound 29b demonstrated reduction of cartilage degradation biomarker (TIINE) levels associated with cartilage protection in a preclinical rat osteoarthritis model...